(Q39032512)

English

mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib

scientific article published on 9 January 2017

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

phase II clinical trial

0 references

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

object named as

Ann-Lii Cheng

3

0 references

author name string

Tim Meyer

1

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Daniel H Palmer

2

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Julia Hocke

4

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Arsène-Bienvenu Loembé

5

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Chia-Jui Yen

6

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

publication date

9 January 2017

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Liver International

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

37

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

1047-1055

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Design and endpoints of clinical trials in hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.13359

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1111%2FLIV.13359

21 January 2018

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FLIV.13359

21 January 2018

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FLIV.13359

21 January 2018

Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.13359

21 January 2018

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FLIV.13359

21 January 2018

Radiologic response to transcatheter hepatic arterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.13359

21 January 2018

EASL and mRECIST responses are independent predictors of survival in hepatocellular carcinoma patients treated with cryoablation

1 reference

https://api.crossref.org/works/10.1111%2FLIV.13359

21 January 2018

mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE).

1 reference

https://api.crossref.org/works/10.1111%2FLIV.13359

21 January 2018

Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization

1 reference

https://api.crossref.org/works/10.1111%2FLIV.13359

21 January 2018

Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation

1 reference

https://api.crossref.org/works/10.1111%2FLIV.13359

21 January 2018

Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.13359

21 January 2018

Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.13359

21 January 2018

Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.13359

21 January 2018

Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FLIV.13359

21 January 2018

Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FLIV.13359

21 January 2018

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FLIV.13359

21 January 2018

Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version).

1 reference

https://api.crossref.org/works/10.1111%2FLIV.13359

21 January 2018

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.13359

21 January 2018

Identifiers

10.1111/LIV.13359

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39032512&oldid=1803362984"